Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.61 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190375 | 0.85 | SYK (0.70) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL191238 | 0.82 | SYK (0.54) | SYKCDC7PDGFRBPDGFRAEGFR | |
| SCHEMBL189926 | 0.81 | SYK (0.46) | SYKEGFRJAK2LCKLYN | |
| SCHEMBL13007742 | 0.80 | SYK (0.67) | SYKCDC7PDGFRBPDGFRAEGFR | |
| SCHEMBL2104157 | 0.80 | SYK (0.64) | SYKCDC7PDGFRBPDGFRAEGFR | |
| SCHEMBL2105369 | 0.79 | SYK (0.68) | SYKCDC7PDGFRBPDGFRAEGFR | |
| SCHEMBL2104371 | 0.79 | SYK (0.68) | SYKCDC7PDGFRBPDGFRAEGFR | |
| SCHEMBL190333 | 0.79 | SYK (0.49) | SYKCDC7PDGFRBPDGFRAEGFR | |
| SCHEMBL653843 | 0.79 | SYK (0.80) | SYKCDC7PDGFRBPDGFRAEGFR | |
| SCHEMBL12389631 | 0.78 | SYK (0.57) | SYKCDC7PDGFRBPDGFRAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814878-B1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1814878-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006068770-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | SSB, SPHK2, PKD2 | SYK 1168/4885CDC7 3761/4885PDGFRB 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.